|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01501 INT MEDICAL
Nominal 
27.350 -0.100 (-0.364%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 752,836 | 28.496% | 585,883 | 464,675 | 358,428 | 286,457 |
| Cost of Sales | (314,766) | 24.219% | (253,397) | (188,930) | (124,013) | (112,015) |
| Gross Profit | 438,070 | 31.756% | 332,486 | 275,745 | 234,415 | 174,442 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (567) | 44 | 21 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 175,128 | 21.223% | 144,468 | 155,691 | 137,085 | 111,913 | |
| Taxation | (21,900) | 105.924% | (10,635) | (15,246) | (20,568) | (15,378) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,229 | -- | (2,120) | 2,515 | 4,837 | 3,079 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 156,457 | 18.786% | 131,713 | 142,960 | 121,354 | 99,614 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (8,637) | -31.398% | (12,590) | (13,892) | (24,003) | (8,125) |
| Depreciation & Amortisation | 47,554 | 28.257% | 37,077 | 30,216 | 21,964 | 18,643 |
| Directors' Emoluments | 9,332 | 34.933% | 6,916 | 2,425 | 1,973 | 3,132 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 92.000 | 16.456% | 79.000 | 86.000 | 73.000 | 79.000 |
| DPS (cts) | 27.000 | -- | 24.000 | 26.000 | 28.500 | 17.500 |
| Dividend Payout Ratio (%) | 29.348% | -- | 30.380% | 30.233% | 39.041% | 22.152% |
| Cash flow per share ($) | 1.074 | -- | 1.087 | 0.438 | 0.577 | 0.727 |
| NBV per share ($) | 9.645 | -- | 9.000 | 8.406 | 7.865 | 7.328 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 100,538,000 |
| %Change | 24.889% |
| EPS / (LPS) | RMB 0.580 |
| NBV Per Share (¥) | RMB 9.538 |